Gene expression profiling and tissue microarray (TMA) demonstrates that increased CD166 expression is correlated with high Gleason score and human castration resistant prostate cancer.

<p>(A) CD166 gene expression from 147 human prostate tumors was analyzed by comparing different Gleason score groups to normal/benign (NL/BN) prostate. (B) Representative IHC staining of CD166 expression from human prostate TMA. Top: hormone naïve primary prostate cancer; Low: castration resistant prostate cancer showing highly intensive immunostaining. Scale bar: 100 µm (left); 10 µm (right). (C) Data from 112 samples were calculated and statistical analysis of CD166 expression of human TMA conducted. NHT: neoadjuvant hormone therapy; CRPC: castrate resistant prostate cancer. Column, mean CD166 staining in NHT and CR tissues. Samples were graded from 0 to +3 representing the range from no staining to heavy staining by visual scoring. Error bar: standard error. Immunoreactivity of CD166 is significantly higher in CRPC group compared with untreated group (p<0.021) or NHT with different treatment times (p<0.0001).